975 related articles for article (PubMed ID: 28716027)
1. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.
Selvey LA; Lim WH; Boan P; Swaminathan R; Slimings C; Harrison AE; Chakera A
BMC Infect Dis; 2017 Jul; 17(1):501. PubMed ID: 28716027
[TBL] [Abstract][Full Text] [Related]
2. CMV mismatch does not affect patient and graft survival in UK renal transplant recipients.
Johnson RJ; Clatworthy MR; Birch R; Hammad A; Bradley JA
Transplantation; 2009 Jul; 88(1):77-82. PubMed ID: 19584684
[TBL] [Abstract][Full Text] [Related]
3. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy.
Harvala H; Stewart C; Muller K; Burns S; Marson L; MacGilchrist A; Johannessen I
J Med Virol; 2013 May; 85(5):893-8. PubMed ID: 23508914
[TBL] [Abstract][Full Text] [Related]
4. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V
Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
Kuo HT; Ye X; Sampaio MS; Reddy P; Bunnapradist S
Transplantation; 2010 Nov; 90(10):1091-8. PubMed ID: 20885340
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the QuantiFERON-CMV assay, CMV viraemia and antiviral treatment following solid organ transplantation in Western Australia.
Thompson G; Boan P; Baumwol J; Chakera A; MacQuillan G; Swaminathan S; Lavender M; Flexman J; James I; John M
Pathology; 2018 Aug; 50(5):554-561. PubMed ID: 29945729
[TBL] [Abstract][Full Text] [Related]
7. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Stevens-Ayers T; Edmison B; Boeckh M; Limaye AP
JAMA; 2020 Apr; 323(14):1378-1387. PubMed ID: 32286644
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus infection in living-donor and cadaveric lung transplantations.
Ohata K; Chen-Yoshikawa TF; Takahashi K; Aoyama A; Motoyama H; Hijiya K; Hamaji M; Menju T; Sato T; Sonobe M; Takakura S; Date H
Interact Cardiovasc Thorac Surg; 2017 Nov; 25(5):710-715. PubMed ID: 29049752
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
Wadhawan M; Gupta S; Goyal N; Vasudevan KR; Makki K; Dawar R; Sardana R; Lal N; Kumar A
Liver Transpl; 2012 Dec; 18(12):1448-55. PubMed ID: 22903934
[TBL] [Abstract][Full Text] [Related]
11. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
Chaiyapak T; Borges K; Williams A; Banh T; Vasilevska-Ristovska J; Allen U; Parekh RS; Hébert D
Transplantation; 2018 Aug; 102(8):1391-1396. PubMed ID: 29377877
[TBL] [Abstract][Full Text] [Related]
12. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
Kılınçkaya Doğan H; Mutlu E; Köksoy S; Yılmaz VT; Koçak H; Çolak D; Mutlu D; Günseren F; Dinçkan A; Aliosmanoğlu İ; Süleymanlar G; Gültekin M
Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease.
Reusing JO; Feitosa EB; Agena F; Pierrotti LC; Azevedo LSF; Kotton CN; David-Neto E
Transpl Infect Dis; 2018 Oct; 20(5):e12929. PubMed ID: 29809309
[TBL] [Abstract][Full Text] [Related]
14. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients.
Reischig T; Nemcová J; Vanecek T; Jindra P; Hes O; Bouda M; Treska V
Antivir Ther; 2010; 15(1):23-30. PubMed ID: 20167988
[TBL] [Abstract][Full Text] [Related]
15. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin.
Gutiérrez CA; Chaparro C; Krajden M; Winton T; Kesten S
Chest; 1998 Apr; 113(4):924-32. PubMed ID: 9554627
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus (CMV) prophylaxis by acyclovir in pre-transplant CMV-positive renal transplant recipients.
Rostaing L; Crespin A; Icart J; Lloveras JJ; Durand D; Martinet O; Didier J
Transpl Int; 1994; 7 Suppl 1():S331-5. PubMed ID: 11271244
[TBL] [Abstract][Full Text] [Related]
18. Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection.
Rittà M; Costa C; Solidoro P; Sidoti F; Libertucci D; Boffini M; Rinaldi M; Baldi S; Cavallo R
Antiviral Res; 2015 Jan; 113():19-26. PubMed ID: 25446337
[TBL] [Abstract][Full Text] [Related]
19. Impact of Prophylaxis vs Pre-emptive Approach for Cytomegalovirus Infection in Kidney Transplant Recipients.
Kır O; Zeytinoğlu A; Arda B; Yılmaz M; Aşçı G; Töz H
Transplant Proc; 2017 Apr; 49(3):537-540. PubMed ID: 28340829
[TBL] [Abstract][Full Text] [Related]
20. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients.
Owers DS; Webster AC; Strippoli GF; Kable K; Hodson EM
Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD005133. PubMed ID: 23450558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
